pioglitazone has been researched along with Allergic Encephalomyelitis in 6 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In EAE (experimental autoimmune encephalomyelitis), agonists of PPARs (peroxisome proliferator-activated receptors) provide clinical benefit and reduce damage." | 1.36 | Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins. ( Boullerne, AI; Feinstein, DL; Peters, JM; Polak, PE; Richardson, JC; Vittoria Simonini, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chedrawe, MAJ | 1 |
| Holman, SP | 1 |
| Lamport, AC | 1 |
| Akay, T | 1 |
| Robertson, GS | 1 |
| Vittoria Simonini, M | 1 |
| Polak, PE | 1 |
| Boullerne, AI | 1 |
| Peters, JM | 1 |
| Richardson, JC | 1 |
| Feinstein, DL | 2 |
| Hucke, S | 1 |
| Floßdorf, J | 1 |
| Grützke, B | 1 |
| Dunay, IR | 1 |
| Frenzel, K | 1 |
| Jungverdorben, J | 1 |
| Linnartz, B | 1 |
| Mack, M | 1 |
| Peitz, M | 1 |
| Brüstle, O | 1 |
| Kurts, C | 1 |
| Klockgether, T | 1 |
| Neumann, H | 1 |
| Prinz, M | 1 |
| Wiendl, H | 1 |
| Knolle, P | 1 |
| Klotz, L | 1 |
| Galea, E | 1 |
| Gavrilyuk, V | 1 |
| Brosnan, CF | 1 |
| Whitacre, CC | 1 |
| Dumitrescu-Ozimek, L | 1 |
| Landreth, GE | 1 |
| Pershadsingh, HA | 1 |
| Weinberg, G | 1 |
| Heneka, MT | 1 |
| Peiris, M | 1 |
| Monteith, GR | 1 |
| Roberts-Thomson, SJ | 1 |
| Cabot, PJ | 1 |
| Niino, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability[NCT00242177] | Phase 1 | 30 participants | Interventional | 2003-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Encephalomyelitis, Autoimmune, Experimental; Humans; Multiple Scl | 2007 |
5 other studies available for pioglitazone and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Pioglitazone is superior to quetiapine, clozapine and tamoxifen at alleviating experimental autoimmune encephalomyelitis in mice.
Topics: Administration, Oral; Animals; Antidepressive Agents; Clozapine; Encephalomyelitis, Autoimmune, Expe | 2018 |
Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins.
Topics: Animals; Bone Morphogenetic Proteins; Carrier Proteins; Cells, Cultured; Encephalomyelitis, Autoimmu | 2010 |
Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antigens, CD; Autoimmunity; CD4-Positive T-Lymphocy | 2012 |
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
Topics: Animals; Cerebellum; Cerebral Cortex; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimen | 2002 |
A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies.
Topics: Adjuvants, Immunologic; Animals; Central Nervous System; Chemotaxis, Leukocyte; Disability Evaluatio | 2007 |